At the present, no prospective comparison has ever been made between chemotherapy and WBRT as upfront treatment for brain metastases. Interestingly, a recent survey suggests that in patients with asymptomatic BMs from NSCLC, platinum-based chemotherapy provides equal benefit to WBRT as treatment of first choice [21].

In our study the multivariate analysis showed no prognostic difference between chemotherapy and WBRT as up-front treatment for BMs, and noteworthy this finding was independent from neurologic status at diagnosis of https://www.selleckchem.com/products/nu7441.html brain metastases. Of note, the multivariate analysis identified local approaches (surgery and SRS) as independent prognostic factors for survival. In this survey, we observed that a local approach was delivered as up-front treatment in approximately 30% of patients, despite the fact that some data suggest that local treatment could be beneficial for many patients with ≤ 3 brain metastases (59% of patients from our series). To this regard, historical data indicate that surgery might significantly prolong survival of patients with single BMs [22, 23], whereas more recently it has been demonstrated that SRS alone might provide equal results in terms of survival

and neurocognitive functioning to SRS plus WBRT in patients with ≤ 4 brain lesions [24]. The discrepancy we found between the number of patients with ≤ 3 brain metastases and those who received a local approach, can be explained selleck products at least in part by the fact that neurosurgery and SRS were available only in one centre. In fact, Selleck Fludarabine when patients with ≤ 3 BMs were analyzed on the basis of the resources available at each center, a higher percentage of patients referring to a comprehensive cancer GDC-0994 molecular weight center was preferentially treated with either surgery

or SRS (group A) compared to that treated in cancer institutions with no local treatments (group B). Surprisingly, time to brain progression for patients treated locally in each group versus those receiving regional/systemic treatments did not differ significantly. In our opinion, this finding can be ascribed to the heterogeneous characteristics of our patients, which reflects the scenario of clinical practice, where the choice of front-line strategies for BMs are influenced not only by the experience of each single physician, but also by the availability of resources. Conclusions Cancer patients with BMs who are deemed eligible for a local approach (SRS, surgery) on the basis of their clinical characteristics might obtain improved survival from such treatment. Neverthless, in order to optimize the treatment of BMs, it becomes of crucial importance, to carefully select patients who should be offered local treatments for BMs. References 1. Posner JB: Brain metastases: 1995. A brief review. J Neurooncol 1996, 27:287–293.PubMedCrossRef 2. Johnson JD, Young B: Demographics of brain metastases.